PharmaKure, a company spun out from the University of Manchester, is looking for investment to fund drug library screening, pre-clinical and early phase human trials.
The company’s first drug, PK-048, was discovered in the 1980s as a drug candidate for Parkinson’s disease, but PharmaKure hopes to reposition it for the treatment of Alzheimer’s disease.